12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Company News  |  Deals

Arena, Eisai deal

The companies said Arena transferred the NDA for weight loss drug Belviq lorcaserin to Eisai. The deal establishes the pharma as the marketing authorization holder responsible for U.S. regulatory activities related to the commercialization of Belviq, including pharmacovigilance requirements. Eisai has marketing rights to lorcaserin in North America and...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >